MGNX — MacroGenics Inc

MacroGenics Inc (MGNX) is a biotechnology company listed on NASDAQ. It is led by Eric Blasius Risser, based in 9704 Medical Center Drive, Rockville, MD, United States, 20850, with about 293 employees. MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Latest reported MGNX revenue for 2025-09-30 was $72.8M. Net income was $16.8M. Revenue was up 227.5% from 2025-06-30 to 2025-09-30. MGNX currently screens at market cap $246.6M.

Use this MGNX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MGNX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MGNX SEC filings page. Lician reads the product cache first so this HTML stays unique to MacroGenics Inc even when a live quote feed is slow.